Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration

Slides:

Advertisements

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Advertisements

Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis George Griesinger, M.D.,

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration Jean-noêl Hugues,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials Ana Cobo, Ph.D., César Diaz, M.D.

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women

Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization.

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study Nicole Hope, M.B., B.S., Hon., Luk.

Effect of the initiation of progesterone supplementation in in vitro fertilization–embryo transfer outcomes: a prospective randomized controlled trial

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women Ioannis E. Messinis, M.D., Ph.D.,

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

Zeev Shoham, M.D. Fertility and Sterility

Impact of submucous myoma on the severity of anemia

Wen-Ling Lee, M. D. , Wei-Min Liu, M. D. , Jong-Ling Fuh, M. D

Increased matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 secretion but unaffected invasiveness of endometrial stromal cells in.

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Long-Ching Kuan, M. D. , Mei-Tsz Su, M. D. , Chin-Ming Wu, M. D

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

Angela R. Baerwald, Ph. D. , Olufemi A. Olatunbosun, M. D. , Roger A

Robert F. Casper, M.D. Fertility and Sterility

Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study Ahmet Erdem, M.D., Mehmet Erdem,

Clinical Assessment of Recombinant Human Follicle-Stimulating Hormone in Stimulating Ovarian Follicular Development Before In Vitro Fertilization fn1

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Robotic-assisted laparoscopic ovarian tissue transplantation

Insulin-like growth factor-II (IGF-II), IGF-binding protein-3 (IGFBP-3), and IGFBP-4 in follicular fluid are associated with oocyte maturation and embryo.

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Effect of letrozole at 2. 5 mg or 5

Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro.

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,

Endocrine gland–derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome.

Aviad Cohen, M. D. , Guy Bibi, M. D. , Benny Almog, M. D

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Effectiveness of highly purified human menopausal gonadotropin vs

The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.

Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins:

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.

Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

Office hysteroscopic early lysis of intrauterine adhesion after transcervical resection of multiple apposing submucous myomas Jehn-Hsiahn Yang, M.D.,

Serum anti-Mullerian hormone dynamics during stimulated cycles by aromatase inhibitor anastrozole and clomiphene citrate in women with infertility H.-H.

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

The gonadotropin-releasing hormone (GnRH)-1 gene, the GnRH receptor gene, and their promoters in patients with idiopathic hypogonadotropic hypogonadism.

Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian.

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

Defining the “sweet spot” for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect.

Ovarian follicular volume and follicular surface area are better indicators of follicular growth and maturation, respectively, than is follicular diameter

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

P-24 Fertility and Sterility Volume 85, Pages S19-S20 (April 2006)

Presentation transcript:

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration Tsung-Hsien Lee, M.D., Ming-Yih Wu, M.D., Hsin-Fu Chen, M.D., Mei-Jou Chen, M.D., Hong-Nerng Ho, M.D., Yu-Shih Yang, M.D., Ph.D. Fertility and Sterility Volume 83, Issue 6, Pages 1700-1707 (June 2005) DOI: 10.1016/j.fertnstert.2004.12.037 Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

FIGURE 1 Flow chart for the present clinical trial. Lee. Follicular growth after GnRH-antagonist. Fertil Steril 2005. Fertility and Sterility 2005 83, 1700-1707DOI: (10.1016/j.fertnstert.2004.12.037) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

FIGURE 2 Detailed analysis of follicular development for the three study groups. The number of large-sized follicles did not differ significantly among the groups, although the SD protocol receiving 3 mg cetrorelix did reveal the lowest number of medium (P=.012 for F-test, P=.003 for t-test between SD and LP) and small (P=.026 for F-test, P=.007 for t-test between SD and LP) follicles. Lee. Follicular growth after GnRH-antagonist. Fertil Steril 2005. Fertility and Sterility 2005 83, 1700-1707DOI: (10.1016/j.fertnstert.2004.12.037) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

FIGURE 3 The dynamic change in mean serum LH levels for the three study groups. The patients from the LP group exhibited the lowest mean serum LH level on the day prior to stimulation with hMG (P=.018 for t-test between MD and LP, P=.039 for t-test between SD and LP). The patients from the SD group demonstrated the greatest mean serum LH level on day 5 of stimulation with hMG (P=.001 for t-test between MD and SD groups, P=.005 for t-test between SD and LP groups). The mean serum LH level dropped immediately subsequent to the administration of 3 mg cetrorelix. Lee. Follicular growth after GnRH-antagonist. Fertil Steril 2005. Fertility and Sterility 2005 83, 1700-1707DOI: (10.1016/j.fertnstert.2004.12.037) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

FIGURE 4 The dynamic change in mean serum E2 levels for the three study groups. The patients from the SD group revealed lower levels of serum E2 than the LP group (P=.037 for t-test). The mean serum E2 level remained static following the injection of 3 mg cetrorelix. Lee. Follicular growth after GnRH-antagonist. Fertil Steril 2005. Fertility and Sterility 2005 83, 1700-1707DOI: (10.1016/j.fertnstert.2004.12.037) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions